PD-L1 expression in pre-treatment tumour samples has been proposed as a marker for clinical response to anti-PD-1/PD-L1 immunotherapy in patients with advanced malignancies, including melanoma, non-small cell lung cancer, kidney cancer, colorectal cancer, and castration-resistant prostate cancer (8, 9). The gene discussed is CD274; the disease is melanoma.